

Maternal Buprenorphine Maintenance and Lactation

Journal of Human Lactation

32, 675-681

DOI: [10.1177/0890334416663198](https://doi.org/10.1177/0890334416663198)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Maternal buprenorphine treatment and fetal neurobehavioral development. American Journal of Obstetrics and Gynecology, 2017, 216, 529.e1-529.e8.	0.7	29
2	Opioid Use in Pregnancy, Neonatal Abstinence Syndrome, and Childhood Outcomes. Obstetrics and Gynecology, 2017, 130, 10-28.	1.2	191
3	Surgical Pain After Transobturator and Retropubic Midurethral Sling Placement. Obstetrics and Gynecology, 2017, 130, 118-125.	1.2	11
4	No. 349-Substance Use in Pregnancy. Journal of Obstetrics and Gynaecology Canada, 2017, 39, 922-937.e2.	0.3	70
5	No 349 " Consommation de substances psychoactives pendant la grossesse. Journal of Obstetrics and Gynaecology Canada, 2017, 39, 938-956.e3.	0.3	2
6	Case Series of Successful Postoperative Pain Management in Buprenorphine Maintenance Therapy Patients. Anesthesia and Analgesia, 2017, 125, 1779-1783.	1.1	39
7	The Clinical Presentation and Nutritional Management of an Infant With Neonatal Abstinence Syndrome. Topics in Clinical Nutrition, 2018, 33, 79-92.	0.2	0
8	Prenatal buprenorphine exposure and neonatal neurobehavioral functioning. Early Human Development, 2018, 117, 7-14.	0.8	24
9	" Doing the Best That I Can for Her" Infant-Feeding Decisions of Mothers Receiving Medication-Assisted Treatment for an Opioid Use Disorder. Journal of Human Lactation, 2018, 34, 535-542.	0.8	26
10	Opioid Use Dependency in the Mother Who Desires to Breastfeed Her Newborn: A Case Study. Journal of Pediatric Health Care, 2018, 32, 223-230.	0.6	2
11	Detection of Drug-Exposed Newborns. Therapeutic Drug Monitoring, 2018, 40, 166-185.	1.0	44
12	Neonatal abstinence syndrome. Nature Reviews Disease Primers, 2018, 4, 47.	18.1	33
13	Supporting breastfeeding for infants born to opioid dependent mothers June 18, 2018. Nursing Outlook, 2018, 66, 496-498.	1.5	2
14	Opioids in Breast Milk: Pharmacokinetic Principles and Clinical Implications. Journal of Clinical Pharmacology, 2018, 58, S151-S163.	1.0	40
15	Does Maternal Buprenorphine Dose Affect Severity or Incidence of Neonatal Abstinence Syndrome?. Journal of Addiction Medicine, 2018, 12, 435-441.	1.4	15
16	Substances of Abuse and the Brain. , 2019, , 85-146.		0
17	Breastmilk feeding for mothers and infants with opioid exposure: What is best?. Seminars in Fetal and Neonatal Medicine, 2019, 24, 95-104.	1.1	18
18	Systematic Review of Newborn Feeding Method and Outcomes Related to Neonatal Abstinence Syndrome. JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing, 2019, 48, 398-407.	0.2	17

#	ARTICLE	IF	CITATIONS
19	Breastfeeding Intention Compared With Breastfeeding Postpartum Among Women Receiving Medication-Assisted Treatment. <i>Journal of Human Lactation</i> , 2019, 35, 71-79.	0.8	15
20	Top Ten Tips Palliative Care Clinicians Should Know About Caring for Serious Illness in Pregnancy. <i>Journal of Palliative Medicine</i> , 2020, 23, 712-718.	0.6	1
21	Sedatives for opioid withdrawal in newborn infants. <i>The Cochrane Library</i> , 2021, 2021, CD002053.	1.5	5
22	Opioid treatment for opioid withdrawal in newborn infants. <i>The Cochrane Library</i> , 2021, 2021, CD002059.	1.5	13
23	A Meta-Analysis of Breastfeeding Effects for Infants With Neonatal Abstinence Syndrome. <i>Nursing Research</i> , 2021, Publish Ahead of Print, .	0.8	12
24	Oxidative Stress Indices Changes in the Hearts of Rat Pups in Response to Maternal Buprenorphine Treatment during Gestation and Lactation. <i>Cardiovascular Toxicology</i> , 2021, , 1.	1.1	1
25	Buprenorphine X-waiver exemption “beyond the basics for the obstetrical provider. <i>American Journal of Obstetrics & Gynecology MFM</i> , 2021, 3, 100451.	1.3	6
26	Addiction management in the outpatient setting. , 2022, , 169-187.		0
27	When Cleft Lip and/or Palate and Antenatal Opioid Exposure Intersect: A Tutorial. <i>Perspectives of the ASHA Special Interest Groups</i> , 0, , 1-13.	0.4	0
28	Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids. <i>Journal of Personalized Medicine</i> . 2022, 12, 2015.	1.1	1